CLDN18.2 targeting co-stimulatory trispecific T cell engager (Zymeworks)

N/A

Report date: 2024/07/05 10:50:59

Base Information

Drug NameCLDN18.2 targeting co-stimulatory trispecific T cell engager (Zymeworks)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionClaudin 18 protein modulators
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesZymeworks Inc
China Registration ClassN/A

Develop Information

Active CompaniesZymeworks Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A